Author: Amelia Whitehart

Digimarc Recognized as Technology Leader

Today Digimarc Corporation (NASDAQ: DMRC), inventor of the Digimarc Discover? platform featuring the imperceptible Digimarc Barcode, announced the company has been recognized for driving innovative solutions into the retail sector. Digimarc is named by ABI Research as a Smart Retail Hot Tech Innovator for 2017. The company was also recognized in IEEE Spectrum for its intellectual property, ranking third for its patent portfolio in the computer software category behind only Microsoft and VMWare, and ahead of software powerhouses including Adobe, Citrix, Oracle, SAP and Symantec.

“Our vision is to enrich everyday living through our patented technologies and applications such as Digimarc Barcode,” said Bruce Davis, chief executive officer, Digimarc. “We have a long tradition of technology innovation and a computing platform that enables future application development and growth by our customers and partners. It’s gratifying to see this recognition of our industry-leading innovation.”

ABI Research identified solutions and innovative companies that are enabling a retail revolution. According to the firm, the selection criteria for “retail hot tech innovators” identified the companies that are the fastest growing in the retail technology industry based on the number of implementations internationally, and the amount of funds raised from capital investors that will continue to fuel their growth.

In “Patent Power 2017,” IEEE Spectrum reports on intellectual property from leading companies. Its Pipeline Power rating ranks patent portfolios by number of U.S. patents granted in the most recent full year (2016) and quality, as measured by statistical assessment of important qualities such as growth, impact, originality and general applicability.

Additional information about Digimarc Barcode can be viewed here.

About Digimarc
Digimarc Corporation (NASDAQ: DMRC) is a pioneer in the automatic identification of everyday objects such as product packaging and virtually any media, including print, images and audio. Based on the patented Intuitive Computing Platform (ICPT), Digimarc provides innovative and comprehensive automatic recognition technologies to simplify search, and transform information discovery through unparalleled reliability, efficiency and security. Digimarc has a global patent portfolio, which includes over 1,100 granted and pending patents. These innovations include state-of-the-art identification technology, Digimarc Barcode, as well as Digimarc Discover? software for barcode scanning and more. Digimarc is based in Beaverton, Oregon, with technologies deployed by major retailers and consumer brands, central banks, U.S. states, film companies and professional sports franchises, among others. Visit digimarc.com and follow us @digimarc to learn more about The Barcode of EverythingT.

SOURCE Digimarc Corporation

By Computers , ,

Benefits of Fasted Cardio

This article will detail a lot of the methods and products used by women bodybuilders to achieve great fitness results while being health safe.

So many questions …. What are the best steroids for women to use and what are the potential benefits and side effects? Almost every female bodybuilder has questions about steroids women can use. Steroids have become somewhat accepted for use by men, at least socially. But there are still many questions about the efficacy.

Like men, women are interested in taking steroids too. There are many reasons for this, but the most common is to get a slim and muscular look, and get rid of fat. Women are more concerned about their physique, that’s why more and more women are used chemical bodybuilders for building a great body.

Legal Anavar is a safe, natural, extremely effective legal alternative to the prescription steroid Oxandrolone, also known as Anavar and goes by many other street names. This legal anabolic is manufactured with the exact same goals in mind as its pharmaceutical counterpart, but without the dangerous side.

When men lift weights they gain more muscle and bulk up, this is because men have more testosterone. Women will not bulk up like men, they will improve muscle tone and shed fat. There is nothing that turns more heads in a gym than a woman with lean sexy muscle. Detailed view : clenbutrol benefits for women

Exercise is a must in order to transform your body, women with hard bodies usually perform some sort of cardio 30-45 minutes every day, followed by 45 minutes to an hour of strength training, most female fitness models train 5-6 days a week.

Clenbuterol (Clen) is a close cousin to “ephedrine” it has been used by movie stars and famous athletes for decades, it acts a powerful fat burner. Clenbuterol allows you to burn stored body fat as energy before burning up other fuel sources preventing muscle loss.

Now that you have a basic idea of how women get ripped and shredded, you should ask yourself, are willing to take steroids? If you are, you should know that you may suffer some of the possible side effects that come with them. The other alternative is to take a legal steroid that will give you similar benefits without harming your body.

CrazyBulk offers a complete line of legal steroids that benefit both male and female bodybuilders and while the majority of the CrazyBulk product line targets men, the company offers tree products that can help women improve the look of their body while helping them eliminate fat and increase lean muscle.

We all carry weight in different places and the last place where that weight seems to come off is the stomach or abdominal area, however it is not practical to think that we can completely eat our way to shredded abs, sure you can eat clean healthy foods but that is not the complete secret to shredded abs. What we can do is watch what we eat and eliminate foods that provoke our body to store fat.

Men and women both have abdominal muscles underneath the fat, the trick here is uncovering them, exercise is key, any kind of cardiovascular exercise such as running, aerobics, or intense weight training can continuously burn fat, and yes if you want more defined abs once they are uncovered abdominal exercises will make them more pronounced and visible.

A cutting cycle is something that should be gradual, there are women who can drop fat in less than a month, but when you diet down all at once not only do you lose fat, you will also lose a lot of muscle; that’s why a gradual 60-day cutting cycle is best.

What is Methodology X

Methodology X is a cutting edge 28 day home workout that is specially tailored for women. The Book is written by Dan Roberts who has been training famous supermodels and A -list actresses for the last two decades. The Book comes in an electronic format (E-Book) that can easily be downloaded to any Apple or Android device including any computer (laptop) tablet or smartphone. Read more on the topic : female fitness model training tips

What is BlackWolf Hunt?

BlackWolf Hunt for women is a premium workout supplement for women to get you through the toughest training sessions. Inta-Workout means you take it while you train. It will keep you strong and help you maintain energy levels no matter how hard the workout is. BlackWolf Hunt helps carry you through the rest of the way so you can train strong with plenty of energy. Read more on the topic : Best intra workout supplements for women

A lot of male and female bodybuilders carry a lot of muscle but for some reason, they lack the solidness, they look bloated and puffy, this usually happens because they either don’t know how to diet or they are putting the wrong supplements and nutrients in their body.

By Health ,

Cardio3 BioSciences teams up with Medisun International

Cardio3 BioSciences teams up with Medisun International to create Cardio3 BioSciences Asia Holdings Ltd, a Joint Venture aimed at conducting pivotal clinical programs in Greater China

• The minimum of 20M€ funding of the Joint Venture over the next three years is secured by local financial investors led by Hong Kong based Medisun International Ltd.
• The clinical program aims to lead to the commercialization of C-Cure® in the People’s Republic of China, Hong Kong and Taiwan.
• Medisun will also bring local regulatory, clinical and market access knowledge, while Cardio3 BioSciences will bring clinical and operational knowhow and expertise.
• With this additional clinical program in Asia, Cardio3 BioSciences will have access to the third largest pharmaceutical market in the world.
• The quality standards of the Asian operations will be managed by Cardio3 BioSciences, with the same rigor as the European and American operations.

Mont-Saint-Guibert, Belgium, 16 JUNE 2014 – Cardio3 BioSciences SA (C3BS) (Euronext Brussels and Paris : CARD), leader in the discovery and development of advanced regenerative therapies for heart disease, today announces it has entered into an agreement with Medisun International Limited, a financial investor based in Hong Kong aiming to build a life science portfolio, for the purpose of creating a joint venture to conduct Phase III clinical trials in Greater China (the People’s Republic of China, Hong Kong and Taiwan) potentially leading to the commercialization of C-Cure® in these territories. Medisun International Limited is also a shareholder of Cardio3 following a capital increase, the first phase of which became effective today.

The Joint Venture, named Cardio3 BioSciences Asia Holdings Ltd, will be created with the purpose to conduct pivotal clinical trials in Greater China, ie the People’s Republic of China, Hong Kong and Taiwan. Cardio3 BioSciences will bring to the Joint Venture the required IP rights to conduct a clinical trial in those geographies, the use of its C-Cure® manufacturing capabilities based in Mont-Saint-Guibert (Belgium) that will produce the clinical lots for the Phase III program, and its clinical and operational knowhow and expertise. Medisun will bring to the joint venture the funding required for the execution of the clinical trials, with a minimum committed of 20M€ over a three year period, as well as local knowledge of the clinical and regulatory environment.

Cardio 3 BioSciences’s ownership in the Joint Venture will be 40%, to be reduced to 30% when clinical trials are running in the three geographies.
A successful outcome of the Phase III clinical program in those geographies would trigger the right for the joint venture company to commercialize C-Cure® in those territories with royalties ranging between 20 and 30% of net sales depending on total revenue of the Joint Venture.

The obligations under the joint venture agreement are still subject to the completion of the second tranche (for 12.5M€) of a 25 M€ investment in Cardio 3 BioSciences by Medisun on 30 June 2014.

With clinical programs ongoing in Europe and Israel, and soon in the USA and Greater China (People’s Republic of China, Hong Kong and Taiwan), Cardio3 BioSciences confirms its leadership in the cardiac regenerative field with its global presence.

Dr Christian Homsy, CEO of Cardio3 BioSciences, said: “We are delighted to have the opportunity to access the world’s third largest pharmaceutical market at limited costs to Cardio3. In cooperation with a reputable local partner, we look forward to soon initiating one or more pivotal trials that would lead us towards commercialization in the world’s fastest growing economy. We are also delighted that both partners are committed to the most rigorous standards of pharmaceutical practices and scientific integrity.”

Mr Michel Lussier, Chairman of Cardio3 BioSciences, added: “With this presence in Greater China, we are very proud to become the first global player in the field of cardiac regenerative medicines, aiming to commercialize our leading edge cell therapy to patients all across the globe.”

Mr Danny Wong, Chairman of Medisun International Holdings Ltd., added: “I am very proud that we are able to pioneer the clinical development of this exciting technology in China and potentially later on in Asia. Our ultimate goal is to deliver this live-saving treatment to countless patients with heart problems.

We shall organize symposia this August in Beijing and Shanghai to promote cell based medicines as well as Cardio3’s technology. Leading experts from Europe, US and Asia will attend this event which will enable us to reach out and unite biomedical experts in this part of the globe.

We are passionate about this project and I am certain that our involvement with Cardio3 as a leader in this field, combined with our local knowledge of the regulatory, healthcare and market access capabilities and expertise, will bring success to all the parties involved.” Read extra details at http://www.medisun.hk/.

By Science